Gene Therapy for GD2 Expressing Solid Tumors is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Medulloblastoma.

A major limiting factor in the success of CAR T cell therapy for the treatment of solid tumors is targeting tumor antigens also found on normal tissues, which poses significant risks to patients. We ...

She has tried dozens of COVID-19 antigen tests—including while sick with COVID-19. Beginning “at the end of September,” US households can again order free tests through CovidTests.gov.

In close collaboration with the lab of Nai-Kong Cheung at MSK and Dane Wittrup at MIT, we have successfully applied this platform in three preclinical tumor models: GPA33 antigen (colorectal cancer); ...

The antibody simultaneously targets GD2 and B7-H3 tumor antigens, demonstrating exceptional specificity for neuroblastoma. Designed to mitigate the severe pain associated with GD2-targeted ...

An antigen is any substance that prompts your body to trigger an immune response against it. Antigens include allergens, bacteria and viruses. Antibodies are Y-shaped proteins that the body produces ...

CD19 chimeric antigen receptor (CAR)-modified T cells have induced dramatic, sustained remissions in children with chemorefractory disease, with a reversible cytokine release syndrome noted.

Neoself-antigens induce autoimmunity in lupus Reactivation of Epstein-Barr virus infection increases the production of neoself-antigens, which induce an autoimmune response, in patients with lupus ...

After 37 years of pioneering health journalism, community engagement, and empowerment through information, we have now ceased operations. This website will be accessible until September 2025, with all ...

Gene Therapy for GD2 Expressing Solid Tumors is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for High-Grade Glioma.